Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: Pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients

Pharmacological Research

Volumn 61, Issue 2, 2010, Pages 167-174

  Premaud A ^a,b,c   Rousseau, A ^a,b,c   Le Meur, Y ^a,b,c   Venisse, N ^d   Loichot, C ^e   Turcant, A ^f   Hoizey, G ^g   Compagnon, P ^h   Hary, L ⁱ   Debruyne, D ^j   Saivin, S ^k   Jacqz Aigrain, E ^l   Marquet, P ^a,b,c  

^a INSERM   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e HÔPITAL CIVIL   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g REIMS UNIVERSITY HOSPITAL   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ AMIENS UNIVERSITY HOSPITAL   (France)

^j CAEN UNIVERSITY HOSPITAL   (France)

^k TOULOUSE UNIVERSITY HOSPITAL   (France)

^l HÔPITAL ROBERT DEBRÉ   (France)

more..

Author keywords

Bayesian dose adjustment; Concentration controlled versus fixed dose trial; Mycophenolate mofetil; Renal transplantation

Indexed keywords

BASILIXIMAB; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BAYES THEOREM; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EXPOSURE; FEASIBILITY STUDY; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT FAILURE;

ACUTE DISEASE; AREA UNDER CURVE; BAYES THEOREM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEASIBILITY STUDIES; FRANCE; GRAFT REJECTION; GRAFT SURVIVAL; GUIDELINE ADHERENCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LINEAR MODELS; MYCOPHENOLIC ACID; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 73949148866     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.09.006     Document Type: Article

References (18)

1. Knight S.R., and Morris P.J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 85 (2008) 1675-1685
2. Hiemke C. Clinical utility of drug measurement and pharmacokinetics-therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol 64 (2008) 159-166
3. Acosta E.P., Gerber J.G., and Adult Pharmacology Committee Of The Aids Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retrovir 18 12 (2002) 825-834
4. Acosta E.P., Henry K., Page L.M., Erice A., Balfour Jr. H.H., and Fletcher C.V. Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. Pharmacotherapy 17 3 (1997) 424-430
5. Fletcher C.V., Acosta E.P., Henry K., Page L.M., Gross C.R., Kawle S.P., et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 64 3 (1998) 331-338
6. Kakuda T.N., Page L.M., Anderson P.L., Henry K., Schacker T.W., Rhame F.S., et al. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob Agents Chemother 45 1 (2001) 236-242
7. Fletcher C.V., Anderson P.L., Kakuda T.N., Schacker T.W., Henry K., Gross C.R., et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16 4 (2002) 551-560
8. Bossi P., Peytavin G., Ait-Mohand H., Delaugerre C., Ktorza N., Paris L., et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 5 5 (2004) 352-359
9. Flechner S.M., Feng J., Mastroianni B., Savas K., Arnovitz J., Moneim H., et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 79 8 (2005) 926-934
10. Torti C., Quiros-Roldan E., Regazzi M., De Luca A., Mazzotta F., Antinori A., et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infect Dis 40 12 (2005) 1828-1836
11. Clevenbergh P., Garraffo R., Durant J., and Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 16 (2002) 2311-2315
12. Shaw L.M., Kaplan B., and Brayman K.L. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem 44 2 (1998) 381-387
13. van Gelder T., Le Meur Y., Shaw L.M., Oellerich M., DeNofrio D., Holt C., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 2 (2006) 145-154
14. Kuypers D.R., de Jonge H., Naesens M., de Loor H., Halewijck E., Dekens M., et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 30 4 (2008) 673-683
15. Le Meur Y., Büchler M., Thierry A., Caillard S., Villemain F., Lavaud S., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 7 11 (2007) 2496-2503
16. van Gelder T., Silva H.T., de Fijter J.W., Budde K., Kuypers D., Tyden G., et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86 8 (2008) 1043-1051
17. Prémaud A., Le Meur Y., Debord J., Szelag J.C., Rousseau A., Hoizey G., et al. Maximum A posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 27 3 (2005) 354-361
18. Prémaud A., Le Meur Y., Rousseau A., and Marquet P. Limited sampling strategy for the estimation of mycophenolate AUC: a large scale study. 8th international congress of therapeutic drug monitoring and clinical toxicology. Basel, Switzerland, 7-11 September (2003) Abstract in Ther Drug Monit 2003;25(4):504